Negative Opinion Of Antigenics' Oncophage By: MarketMinute.com Stock News October 21, 2009 at 14:27 PM EDT European regulators will issue a negative opinion of Antigenics' (Nasdaq: AGEN) cancer vaccine Oncophage sending the stock price plummeting 88 cents to $1.21.